Transforming the treatment of B cell-mediated autoimmune diseases

Cabaletta Bio is utilizing its innovative therapeutic platform of autologous chimeric autoantibody receptor (CAAR) T cells to pursue the development of first-in-class therapies for autoimmune diseases. The company’s novel approach is designed to precisely ablate specific autoantibody -producing B cells while sparing normal antibody-producing B cells that protect the body from infection.

The company’s lead therapeutic program is a potential treatment for a prototypical B cell-mediated autoimmune disease, mucosal pemphigus vulgaris (mPV).  mPV is a rare autoimmune disorder that causes painful blisters and sores on mucous membranes such as the mouth, nose, throat, and genitals, leading to severe and sometimes debilitating and life-altering effects.

Cabaletta Bio's second product candidate is in muscle specific kinase myasthenia gravis (MuSK MG), which is an autoimmune disease induced by autoantibodies targeting the neuromuscular junction, or NMJ, that can lead to life-threatening muscle weakness.

Cabaletta Bio is also pursuing a second product candidate within PV that targets mucocutaneous PV, an autoimmune skin disorder characterized by the loss of intercellular adhesion of keratinocytes that results in blistering of the skin as well as the mucous membranes.

Publication Highlight

July 8, 2016
Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease
Christoph T. Ellebrecht, Vijay G. Bhoj, Arben Nace, Eun Jung Choi, Xuming Mao, Michael Jeffrey Cho,Giovanni Di Zenzo, Antonio Lanzavecchia, John T. Seykora, George Cotsarelis, Michael C. Milone, Aimee S. Payne

Publication Link